ESTRO 2024 - Abstract Book

S1089

Clinical - Gynaecology

ESTRO 2024

Keywords: Hyperthermia, Cervical cancer, abscopal effect

References:

[1] Minnaar CA, Kotzen JA, Ayeni OA, et al. (2019) The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial. PLOS ONE 14(6): e0217894. https://doi.org/10.1371/journal.pone.0217894 [2] Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers. 2022; 14(3):656. https://doi.org/10.3390/cancers14030656 [3] Minnaar CA, Kotzen JA, Naidoo T, et al. Analysis of the effects of mEHT on the treatment-related toxicity and quality of life of HIV-positive cervical cancer patients. Int J Hyperthermia. 2020;37(1):263-272. doi: 10.1080/02656736.2020.1737253. PMID: 32180481. [4] Minnaar CA, Kotzen JA, Ayeni OA, Vangu MD, Baeyens A. Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients. Front Oncol. 2020 Mar 24;10:376. doi: 10.3389/fonc.2020.00376. PMID: 32266151; PMCID: PMC7105641.

2558

Poster Discussion

Enhancing locally advanced cervical cancer treatment with hyperthermia-induced dose escalation

Carolina Carrapiço-Seabra, Anton Rink, Gerard C. van Rhoon, Sergio Curto

Erasmus MC Cancer Institute, Department of Radiotherapy, Rotterdam, Netherlands

Purpose/Objective:

Hyperthermia, the elevation of target temperature up to 44ºC, is clinically used as a concomitant cancer treatment that enhances the effects of radiotherapy. In the treatment of locally advanced cervical cancer (LACC), different studies reported that adding hyperthermia to radiotherapy results in a significant improvement in local control and overall survival compared to radiotherapy alone. In this study, biological modelling was applied to quantify the effect of radiosensitisation in LACC patients to evaluate the enhancement in equivalent dose (EQD2) for the combined treatment of radiotherapy and hyperthermia.

Material/Methods:

Fourteen patients diagnosed with LACC that were treated using hyperthermia as adjunct to radiotherapy, were included. External beam radiotherapy (EBRT) was given in 23–25 daily fractions of 1.8–2.25Gy per fraction, five times a week. Hyperthermia was prescribed once weekly to a total of five fractions during the five weeks of EBRT. Clinically, a brachytherapy boost is given, but since hyperthermia is only given during EBRT, this is not relevant for this study. The hyperthermia treatment was performed in a MR-compatible system (BSD-2000-3D,